Wintest
6721
D. Western Therapeutics Institute
4576
Ridge-i
5572
Forside
2330
River Eletec
6666
(Q2)Mar 31, 2024 | (Q1)Dec 31, 2023 | (FY)Sep 30, 2023 | (Q4)Sep 30, 2023 | (Q3)Jun 30, 2023 | (Q2)Mar 31, 2023 | (Q1)Dec 31, 2022 | (FY)Sep 30, 2022 | (Q4)Sep 30, 2022 | (Q3)Jun 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 26.07%257.84M | -14.72%177.62M | 12.19%765.9M | 8.28%183.53M | -5.10%169.58M | 25.50%204.52M | 21.41%208.28M | -88.17%682.7M | -84.69%169.5M | -86.99%178.69M |
Cost of revenue | 3.31%116.77M | -0.76%110.72M | 16.29%474.94M | 24.49%137.74M | 7.96%112.61M | 27.31%113.03M | 6.58%111.57M | -46.25%408.41M | -34.43%110.65M | -36.85%104.3M |
Gross profit | 54.19%141.07M | -30.83%66.9M | 6.07%290.95M | -22.20%45.78M | -23.41%56.97M | 23.33%91.49M | 44.62%96.71M | -94.53%274.29M | -93.73%58.85M | -93.84%74.39M |
Operating expense | 126.92%142.47M | 74.49%102.52M | 34.64%254.37M | 86.66%81.79M | 5.52%51.05M | 27.36%62.78M | 23.84%58.75M | -96.05%188.93M | -95.18%43.82M | -96.21%48.37M |
Operating profit | -104.87%-1.4M | -193.86%-35.62M | -57.15%36.58M | -339.51%-36.01M | -77.23%5.92M | 15.35%28.71M | 95.38%37.96M | -62.36%85.36M | -48.01%15.03M | 138.11%26.01M |
Net non-operating interest income (expenses) | 140.77%6.86M | -46.76%3.46M | -310.86%-13.69M | -154.43%-8.72M | 87.05%5.36M | -2,286.36%-16.84M | 3.47%6.51M | 101.10%6.49M | 97.88%-3.43M | 101.90%2.87M |
Non-operating interest income | 103.66%10.4M | -11.30%9.02M | 60.99%30.07M | 452.49%8.23M | -5.29%6.57M | -31.97%5.11M | 54.71%10.17M | -88.48%18.68M | -106.29%-2.33M | -81.97%6.94M |
Non-operating interest expense | -84.12%3.48M | -21.77%2.86M | -0.10%12.17M | 236.29%3.68M | -520.39%-17.11M | 225.81%21.94M | 1,189.08%3.66M | -98.38%12.18M | -99.45%1.09M | -97.85%4.07M |
Total other finance cost | --49K | --2.69M | --31.59M | --13.27M | ---- | ---- | ---- | ---- | ---- | ---- |
Net investment income | -32.00%11.13M | 58.28%-11.5M | -115.81%-22.49M | -61.46%11.42M | -133.66%-22.73M | -62.53%16.37M | -2,088.17%-27.56M | 292.87%142.25M | -58.94%29.64M | 302.89%67.53M |
Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
Gain(Loss) on derecognition of available-for-sale financial assets | ||||||||||
Income from associates and other participating interests | 69.35%87M | -2,140.15%-585.58M | -741.52%-493.81M | -400.51%-562.91M | 122.98%43.86M | 231.98%51.37M | -61.36%-26.14M | -200.56%-58.68M | 192.32%187.32M | -197.39%-190.87M |
Special income (charges) | 0 | 0 | 99.56%-348K | 99.15%-88K | 104.83%1.71M | 73.58%-6.57M | 151.79%4.6M | 85.89%-79.47M | 98.02%-10.34M | -305.49%-35.38M |
Less:Write off | --0 | --0 | -99.56%348K | -99.15%88K | -104.83%-1.71M | -73.58%6.57M | -151.79%-4.6M | -86.09%79.47M | -98.02%10.34M | 305.49%35.38M |
Other non-operating income (expenses) | -86.50%127K | 73.66%1.82M | -64.01%6.78M | -60.65%5.88M | -224.23%-1.08M | -48.72%941K | -13.39%1.05M | 99.30%18.85M | 192.88%14.93M | -16.01%871K |
Income before tax | 40.21%103.73M | -17,401.03%-627.41M | -524.18%-486.98M | -353.23%-590.42M | 125.62%33.04M | 900.81%73.98M | -211.16%-3.59M | 105.50%114.81M | 112.04%233.16M | -235.88%-128.97M |
Income tax | 21.51%20.37M | -64.88%3.44M | -56.04%26.21M | 93.68%-1.49M | -96.18%1.14M | -63.78%16.76M | 37.44%9.81M | -91.77%59.63M | -107.13%-23.55M | -74.70%29.77M |
Net income | 45.69%83.36M | -4,611.40%-630.86M | -1,030.06%-513.2M | -329.42%-588.93M | 120.10%31.9M | 247.18%57.22M | -242.54%-13.39M | 101.96%55.18M | 111.32%256.71M | -1.72%-158.74M |
Net income continuous operations | 45.69%83.36M | -4,611.40%-630.86M | -1,030.04%-513.2M | -329.41%-588.93M | 120.10%31.9M | 247.18%57.22M | -242.54%-13.39M | 101.96%55.18M | 111.32%256.71M | -1.72%-158.74M |
Noncontrolling interests | 1.77M | |||||||||
Net income attributable to the company | 41.30%83.36M | -4,059.95%-630.86M | -1,030.06%-513.2M | -329.42%-588.93M | 120.10%31.9M | 251.74%59M | -287.95%-15.17M | 104.66%55.18M | 127.12%256.71M | -81.72%-158.74M |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | 41.30%83.36M | -4,059.95%-630.86M | -1,030.06%-513.2M | -329.42%-588.93M | 120.10%31.9M | 251.74%59M | -287.95%-15.17M | 104.66%55.18M | 127.12%256.71M | -81.72%-158.74M |
Gross dividend payment | ||||||||||
Basic earnings per share | 18.79%1.96 | -3,438.10%-14.86 | -988.96%-13.69 | -319.92%-15.79 | 119.59%0.87 | 251.38%1.65 | -281.82%-0.42 | 104.65%1.54 | 127.13%7.18 | -81.22%-4.44 |
Diluted earnings per share | 18.79%1.96 | -3,438.10%-14.86 | -988.96%-13.69 | -319.93%-15.79 | 117.95%0.7969 | 251.37%1.65 | -281.82%-0.42 | 104.65%1.54 | 127.12%7.1797 | -81.22%-4.44 |
Dividend per share | ||||||||||
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |